Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion

Reuters2026/08/06 15:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab revenue rose 25% to USD 2.05 billion in the first half of 2026.
Operating profit edged up to USD 555 million; adjusted operating profit (non-IFRS) increased to USD 656 million.
Royalty revenue climbed 24% to USD 1.71 billion, driven by higher DARZALEX and Kesimpta royalties.
Global net sales of EPKINLY/TEPKINLY rose 48% to USD 312 million; cost of product sales increased 51% to USD 149 million.
Raised 2026 revenue guidance to USD 4.33-4.53 billion; highlighted positive Phase 3 epcoritamab data in relapsed/refractory DLBCL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion

You may also like

Crypto prices